Drug Combination Details
| General Information of the Combination (ID: C30252) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Empagliflozin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Diminished ovarian reserve
[ICD-11: 5A80]
|
Phase 3 | [1] | ||
|
Type 2 diabetes mellitus
[ICD-11: 5A11]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Experimental
Result(s) |
Initial combinations of empagliflozin + metformin for 24 weeks significantly reduced HbA1c versus empagliflozin once daily and metformin twice daily, without increased hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated. | |||||
